Akers Logo Top  
Akers Logo Bottom

index page logos 




15 NOV 2013     Unaudited Results for the Nine Months Ended 30 September 2013

The results and those for the comparable period in 2012 are stated in US GAAP, as the Company had previously announced its proposal to list on the NASDAQ Capital Market (“NASDAQ”).  It is intended that following the NASDAQ listing, the Company’s final results for the year ending 31 December 2013 will also be reported in US GAAP.  

22 AUG 2013     Interim Results for the Six Months Ended 30 June 2013

We are pleased to announce the Company’s performance for the six months ended 30 June of the current financial year. Revenue in the first half of 2013 was $2,639,085 (H1 2012: $787,194).EBITDA was $369,324 (H1 2012: Loss of $782,580). Profit before Tax was $90,235 (H1 2012: Loss of $1,023,283). The Company continues to be debt-free with current assets in cash and cash equivalents of $1,553,884 (H1 2012: $482,950). Gross Profit Margin was slightly down to 47% (H1 2012: 50%), due to increased manufacturing costs incurred in the ramp up to produce CHUBE devices.

08 AUG 2013     Proposed NASDAQ Listing

The Company announced that it is seeking a listing of the Company's shares on The NASDAQ Capital Market ("NASDAQ").  Simultaneous with the NASDAQ listing, the Company is also seeking to raise additional capital via a registered public offering (the "Offering") of approximately $15,000,000 of its common stock (the "Securities").  The Company has today has filed with the US Securities and Exchange Commission ("SEC") a registration statement on Form S-1 relating to the proposed Offering.

01 JUL 2013     Appointment of Non-Executive Directors

ABI is pleased to announce that Gavin Moran and Thomas Knox will be appointed to the board as Non-Executive Directors with effect from 1 July 2013.

26 JUN 2013    Preliminary Results for the Year Ended 31 December 2012

The annual financial results for the Company, in US Dollars, for the year ended 31 December 2012 have been released to the market.  The Annual Report and Accounts has been posted to the ABI website.

13 JUN 2013    Extension of Licence and Supply Agreement -$1.6 million share subscription

ABI is pleased to announce that it has extended its licence and supply agreement dated 19 June 2012 (the "Licence and Supply Agreement") with Chubeworkx Guernsey Limited ("Chubeworkx") to cover the United States, Canada and Mexico.  In addition, Chubeworkx has agreed to subscribe for 80,000,000 new common shares (the "Subscription Shares") in the Company for a total price of $1,600,000 (the "Subscription").

10 APR 2013    Trading Update

ABI is pleased to announce that it has today received a second order from Chubeworkx Guernsey Ltd (“Chubeworkx”) for 1.4 million CHUBE‐branded, disposable breath alcohol detectors taking Chubeworkx’s orders to date to 4.9 million.  In addition, and as previously announced, Chubeworx has also paid a licensing fee of $1.0m (the majority of which will be accounted for in the current year), bringing the total revenue with Chubeworkx, and its associated marketing company en10 Limited, to over $2m for 2013.

19 FEB 2013    Update on French Certification for Breathalysers & Product Launch; Trading Update

ABI is pleased to announce that its proprietary disposable breath alcohol detectors will be formally launched to the French market this afternoon by ABI’s partners Chubeworkx Guernsey Ltd and (en)10 (Global) Ltd.   The national reference laboratory of France, Laboratoire National de Métrologie et d'Essais (“LNE”), has recommended that the Company’s breath alcohol detector is in compliance with the quality criteria defined in French Standard NF X 20-702 for disposable breathalysers and the final award of the NF Marque (“NF Mark”) from the Comité de Marque is expected this week.  In addition, the Company is also pleased to report that sales of its test for heparin-induced thrombocytopenia ("HIT"), PIFA Heparin/PF4, have continued to grow strongly with revenues for the first six weeks of 2013 exceeding those for the whole of the first quarter of 2012.

11 DEC 2012    3.5m unit Order for Breath Alcohol Tubes; Part Receipt of Licence Fee

The Company is pleased to announce that it has received a purchase order to manufacture 3.5 million units of a custom breath alcohol detector, based on the Company’s BreathScan product, for $1.05 million. The order will support the entrance of Sono International, Ltd. (“SONO”), a London-based multinational corporation, into the French disposable breath alcohol detector marketplace.

10 DEC 2012    Notice of Annual General Meeting 

ABI is pleased to announce that a notice of the Company’s Annual General Meeting, to be held at 11h00 EST on 20 December 2012 at RiverWinds in Thorofare New Jersey 08086, USA, has been posted to shareholders. All shareholders are welcome to attend in person or issue a proxy to vote on the resolutions at the Meeting.

26 NOV 2012   Distribution Partnership Forged in China

The Company is pleased to announce the signing of a distribution agreement with Novotek Therapeutics Inc., a Beijing‐based pharmaceutical and in vitro diagnostic business development corporation, for ABI’s innovative Particle ImmunoFiltration Assay ("PIFA") products. The multi‐year agreement assigns exclusive sales and marketing rights for the products to Novotek in Mainland China.

17 SEP 2012    $675,000 Private Placing

ABI is pleased to announce the investment of US entrepreneur and politian,Thomas J. Knox through the purchase of 30M common shares and 10M preferred shares.  Knox is the Chief Executive Officer of Knox Consulting Group and Indecs Corp.



All Products Proudly Manufactured in the USA

Government & Defense Procurement Information 



For additional information, please call +1 856 848 2116 or 1.800.451.TEST.




© 2014 Akers Biosciences, Inc. All Rights Reserved.
Technical Services